According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...
According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...
At the 2024 SOHO meeting, Prithviraj Bose, MD, discusses currently available JAK inhibitors for the treatment of myelofibrosis, highlighting ruxolitinib, fedratinib, pacritinib, and momelotinib.
At the 2024 SOHO meeting, Prithviraj Bose, MD, discusses currently available JAK inhibitors for the treatment of myelofibrosis, highlighting ruxolitinib, fedratinib, pacritinib, and momelotinib.
At the 2024 SOHO meeting, John Mascarenhas, MD, shares highlights from a discussion on the utilization and selection of optimal JAK inhibitor therapies for the treatment of patients with myelofibrosis.
At the 2024 SOHO meeting, John Mascarenhas, MD, shares highlights from a discussion on the utilization and selection of optimal JAK inhibitor therapies for the treatment of patients with myelofibrosis.
Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.
Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.
True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...
True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...
Prithviraj Bose, MD, discusses novel developments and future potential in myelofibrosis treatment, highlighting BET inhibitors, PIM kinase inhibitors, and phase 3 trial data on imetelstat, and luspatercept.
Prithviraj Bose, MD, discusses novel developments and future potential in myelofibrosis treatment, highlighting BET inhibitors, PIM kinase inhibitors, and phase 3 trial data on imetelstat, and luspatercept.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...
According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...
At the 2024 SOHO meeting, Prithviraj Bose, MD, discusses currently available JAK inhibitors for the treatment of myelofibrosis, highlighting ruxolitinib, fedratinib, pacritinib, and momelotinib.
At the 2024 SOHO meeting, Prithviraj Bose, MD, discusses currently available JAK inhibitors for the treatment of myelofibrosis, highlighting ruxolitinib, fedratinib, pacritinib, and momelotinib.
Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.
Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.
Triple-negative myelofibrosis was found to be continually associated with decreased survival in addition to enhanced aggressive behavior with higher rates of leukemic transformation as well as a shorter duration of response to ruxolitinib,...
Triple-negative myelofibrosis was found to be continually associated with decreased survival in addition to enhanced aggressive behavior with higher rates of leukemic transformation as well as a shorter duration of response to ruxolitinib,...
Long-term follow-up results from a phase 2 trial highlight the promising efficacy of azacitidine in combination with ruxolitinib for patients with myelofibrosis.
Long-term follow-up results from a phase 2 trial highlight the promising efficacy of azacitidine in combination with ruxolitinib for patients with myelofibrosis.
Pelabresib plus ruxolitinib significantly reduced splenomegaly and improved anemia and bone marrow fibrosis compared with placebo plus ruxolitinib among JAK-inhibitor-treatment-naïve patients with myelofibrosis, according to updated phase 3...
Pelabresib plus ruxolitinib significantly reduced splenomegaly and improved anemia and bone marrow fibrosis compared with placebo plus ruxolitinib among JAK-inhibitor-treatment-naïve patients with myelofibrosis, according to updated phase 3...
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...
True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...
True or False: Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that demonstrated insight into the appropriateness of the symptom change threshold used in the phase 3...
True or False: Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that demonstrated insight into the appropriateness of the symptom change threshold used in the phase 3...
The addition of parsaclisib to stable-dose ruxolitinib treatment ___ splenomegaly and ___ symptom scores among patients with primary or secondary myelofibrosis who did not have optimal responses to ruxolitinib alone, according to findings...
The addition of parsaclisib to stable-dose ruxolitinib treatment ___ splenomegaly and ___ symptom scores among patients with primary or secondary myelofibrosis who did not have optimal responses to ruxolitinib alone, according to findings...
What was the key finding of a population-based retrospective cohort study analyzing the outcomes of higher-risk patients with myelofibrosis treated with ruxolitinib in an unselected real-world population?
What was the key finding of a population-based retrospective cohort study analyzing the outcomes of higher-risk patients with myelofibrosis treated with ruxolitinib in an unselected real-world population?
True or False: Findings from a retrospective observational study show that ropeginterferon alfa-2b demonstrated high response rates and tolerable safety among young high-risk patients with Philadelphia chromosome-negative myeloproliferative...
True or False: Findings from a retrospective observational study show that ropeginterferon alfa-2b demonstrated high response rates and tolerable safety among young high-risk patients with Philadelphia chromosome-negative myeloproliferative...
True or False: Interim results from the phase 4 JAKoMO trial indicated that ruxolitinib demonstrated safety and efficacy among elderly Janus kinase (JAK) inhibitor-naïve patients with myelofibrosis in the real-world setting.
True or False: Interim results from the phase 4 JAKoMO trial indicated that ruxolitinib demonstrated safety and efficacy among elderly Janus kinase (JAK) inhibitor-naïve patients with myelofibrosis in the real-world setting.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...
According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...
Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.
Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.
Triple-negative myelofibrosis was found to be continually associated with decreased survival in addition to enhanced aggressive behavior with higher rates of leukemic transformation as well as a shorter duration of response to ruxolitinib,...
Triple-negative myelofibrosis was found to be continually associated with decreased survival in addition to enhanced aggressive behavior with higher rates of leukemic transformation as well as a shorter duration of response to ruxolitinib,...
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
Increasing the dose of ropeginterferon and implementing it earlier driven by high phlebotomy needs improved efficacy outcomes among patients with low-risk polycythemia vera, according to a phase 2 study.
Increasing the dose of ropeginterferon and implementing it earlier driven by high phlebotomy needs improved efficacy outcomes among patients with low-risk polycythemia vera, according to a phase 2 study.
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
